Richmond, BC, December 13, 2021--Neovasc Inc. (NASDAQ , TSX: NVCN) announced that its Neovasc Reducer™ system has been granted Prise en Charge Transitoire (PECT) reimbursement in France by the national health authority, Haute Autoritde Sant (HAS).The decision will be officialized upon publication in the French Journal Officiel.

Richmond, BC, January 7, 2020--Neovasc, Inc. (NASDAQ, TSX: NVCN): NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that it has been selected as a finalist in this year's Fierce Innovation Awards - LifeSciences Edition, a peer reviewed awards program from the publisher of FierceBiotech and FiercePharma.

Richmond, BC, April 5, 2019--Neovasc (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that the Higher Regional Court in Munich, Germany, on appeal by Neovasc, has dismissed the case in full, brought by Edwards Lifesciences CardiAQ LLC against Neovasc in Germany.

Richmond, BC, February 4, 2019--Neovasc Inc. (NASDAQ: NVCN)(TSX: NVCN) announced that it has completed the Phase 1 requirements of the TIARA-II study required by the bi-phasic study design in both Germany and the United Kingdom and has received approval to proceed with Phase 2 of the TIARA-II study for its Tiara™ transcatheter mitral valve replacement device.

Richmond, BC, February 1, 2019--Neovasc Inc. (NASDAQ:NVCN) (TSX:NVCN) has announced that, pursuant to a settlement reached with Edwards Lifesciences PVT, Inc. and Edwards Lifesciences (Canada) Inc., the patent infringement action that Edwards had previously commenced in the Federal Court of Canada against Neovasc, Boston Scientific and Livanova, will be dismissed on a no-costs basis.

Richmond, BC, January 3, 2019--Neovasc Inc. (NASDAQ:NVCN)(TSX:NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that it has received ISO 13485:2016 certification, an internationally recognized quality standard specific to the medical device industry.

Richmond, BC, December 11, 2018--Neovasc, Inc. (NASDAQ: NVCN TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, reported financial results for the third quarter ended September 30, 2018.

Richmond, BC, November 8, 2018--Neovasc Inc. (NASDAQ: NVCN) (TSX: NVCN) announced that the U.S. Food and Drug Administration has granted Breakthrough Device designation to the Neovasc Reducer, a medical device for the treatment of refractory angina, which is not currently approved for commercial sale in the U.S.

Richmond, BC, July 9, 2018--Neovasc Inc. (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced that its Board of Directors has elected Steve Rubin as Chairman of the Board, effective immediately. Rubin succeeds Paul Geyer, who will remain a Director of the Board.